{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["SARS-CoV-2", "VV116", "healthy subjects", "nucleoside analog", "pharmacokinetics", "safety"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35296780", "DateCompleted": {"Year": "2022", "Month": "12", "Day": "02"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "02"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "03", "Day": "16"}], "Language": ["eng"], "ELocationID": ["10.1038/s41401-022-00895-6"], "Journal": {"ISSN": "1745-7254", "JournalIssue": {"Volume": "43", "Issue": "12", "PubDate": {"Year": "2022", "Month": "Dec"}}, "Title": "Acta pharmacologica Sinica", "ISOAbbreviation": "Acta Pharmacol Sin"}, "ArticleTitle": "Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects.", "Pagination": {"StartPage": "3130", "EndPage": "3138", "MedlinePgn": "3130-3138"}, "Abstract": {"AbstractText": ["VV116 (JT001) is an oral drug candidate of nucleoside analog against SARS-CoV-2. The purpose of the three phase I studies was to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of VV116 in healthy subjects, as well as the effect of food on the pharmacokinetics and safety of VV116. Three studies were launched sequentially: Study 1 (single ascending-dose study, SAD), Study 2 (multiple ascending-dose study, MAD), and Study 3 (food-effect study, FE). A total of 86 healthy subjects were enrolled in the studies. VV116 tablets or placebo were administered per protocol requirements. Blood samples were collected at the scheduled time points for pharmacokinetic analysis. 116-N1, the metabolite of VV116, was detected in plasma and calculated for the PK parameters. In SAD, AUC and C<sub>max</sub> increased in an approximately dose-proportional manner in the dose range of 25-800\u2009mg. T<sub>1/2</sub> was within 4.80-6.95\u2009h. In MAD, the accumulation ratio for C<sub>max</sub> and AUC indicated a slight accumulation upon repeated dosing of VV116. In FE, the standard meal had no effect on C<sub>max</sub> and AUC of VV116. No serious adverse event occurred in the studies, and no subject withdrew from the studies due to adverse events. Thus, VV116 exhibited satisfactory safety and tolerability in healthy subjects, which supports the continued investigation of VV116 in patients with COVID-19."], "CopyrightInformation": "\u00a9 2022. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}], "LastName": "Qian", "ForeName": "Hong-Jie", "Initials": "HJ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}], "LastName": "Wang", "ForeName": "Yu", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}], "LastName": "Zhang", "ForeName": "Meng-Qi", "Initials": "MQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}, {"Identifier": [], "Affiliation": "Lingang Laboratory, Shanghai, 201602, China."}], "LastName": "Xie", "ForeName": "Yuan-Chao", "Initials": "YC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}], "LastName": "Wu", "ForeName": "Qing-Qing", "Initials": "QQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}], "LastName": "Liang", "ForeName": "Li-Yu", "Initials": "LY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}], "LastName": "Cao", "ForeName": "Ye", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinical Department, Vigonvita Life Sciences Co., Ltd, Suzhou, 215123, China."}], "LastName": "Duan", "ForeName": "Hua-Qing", "Initials": "HQ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Clinical Department, Vigonvita Life Sciences Co., Ltd, Suzhou, 215123, China."}], "LastName": "Tian", "ForeName": "Guang-Hui", "Initials": "GH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, 200126, China."}], "LastName": "Ma", "ForeName": "Juan", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, 200126, China."}], "LastName": "Zhang", "ForeName": "Zhuo-Bing", "Initials": "ZB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research and Development Department, Shanghai Junshi Biosciences Co., Ltd, Shanghai, 200126, China."}], "LastName": "Li", "ForeName": "Ning", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}], "LastName": "Jia", "ForeName": "Jing-Ying", "Initials": "JY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Phase 1 Clinical Research Center, Huashan Hospital, Fudan University, Shanghai, 200040, China."}], "LastName": "Zhang", "ForeName": "Jing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory Basis of Xinjiang Indigenous Medicinal Plants Resource Utilization, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Urumqi, 830011, China."}], "LastName": "Aisa", "ForeName": "Haji Akber", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}], "LastName": "Shen", "ForeName": "Jing-Shan", "Initials": "JS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}], "LastName": "Yu", "ForeName": "Chen", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China."}, {"Identifier": [], "Affiliation": "Lingang Laboratory, Shanghai, 201602, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China."}], "LastName": "Jiang", "ForeName": "Hua-Liang", "Initials": "HL"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China. zhangwenhong@fudan.edu.cn."}], "LastName": "Zhang", "ForeName": "Wen-Hong", "Initials": "WH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China. wangzhen@lglab.ac.cn."}, {"Identifier": [], "Affiliation": "CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. wangzhen@lglab.ac.cn."}, {"Identifier": [], "Affiliation": "Lingang Laboratory, Shanghai, 201602, China. wangzhen@lglab.ac.cn."}], "LastName": "Wang", "ForeName": "Zhen", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Central Laboratory, Shanghai Xuhui Central Hospital/Xuhui Hospital, Fudan University, Shanghai, 200031, China. gyliu@shxh-centerlab.com."}, {"Identifier": [], "Affiliation": "Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, 200031, China. gyliu@shxh-centerlab.com."}], "LastName": "Liu", "ForeName": "Gang-Yi", "Initials": "GY"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Acta Pharmacol Sin", "NlmUniqueID": "100956087", "ISSNLinking": "1671-4083"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Nucleosides"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Nucleosides"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Healthy Volunteers"}, {"QualifierName": [], "DescriptorName": "Double-Blind Method"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "Area Under Curve"}, {"QualifierName": [], "DescriptorName": "China"}, {"QualifierName": [], "DescriptorName": "Administration, Oral"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}], "CoiStatement": "HQD and GHT are the employees of Vigonvita Life Science Co., Ltd, the sponsor of the study. JM, ZBZ, and NL are the employees of Shanghai Junshi Biosciences Co., Ltd., the parent company of the co-sponsor Shanghai JunTop Biosciences Co., Ltd. YCX, JSS, and HLJ filed a patent application on antiviral nucleoside analogs. The remaining authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care. Clin Infect Dis. 2021;73:e4166\u2013e74. doi: 10.1093/cid/ciaa1041.", "ArticleIdList": ["10.1093/cid/ciaa1041", "PMC7454434", "32706859"]}, {"Citation": "Du L, Yang Y, Zhang X. Neutralizing antibodies for the prevention and treatment of COVID-19. Cell Mol Immunol. 2021;18:2293\u2013306. doi: 10.1038/s41423-021-00752-2.", "ArticleIdList": ["10.1038/s41423-021-00752-2", "PMC8424621", "34497376"]}, {"Citation": "Wang F, Li L, Dou Y, Shi R, Duan X, Liu H, et al. Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants. Emerg Microbes Infect. 2022;11:548\u201351. doi: 10.1080/22221751.2022.2032374.", "ArticleIdList": ["10.1080/22221751.2022.2032374", "PMC8843163", "35060840"]}, {"Citation": "Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. J Am Med Assoc. 2021;326:35\u201345. doi: 10.1001/jama.2021.8565.", "ArticleIdList": ["10.1001/jama.2021.8565", "PMC8156175", "34037666"]}, {"Citation": "Rosenberg ES, Dorabawila V, Easton D, Bauer UE, Kumar J, Hoen R, et al. Covid-19 vaccine effectiveness in New York State. N Engl J Med. 2022;386:116\u201327. doi: 10.1056/NEJMoa2116063.", "ArticleIdList": ["10.1056/NEJMoa2116063", "PMC8693697", "34942067"]}, {"Citation": "Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586\u201393. doi: 10.1126/science.abl4784.", "ArticleIdList": ["10.1126/science.abl4784", "34726479"]}, {"Citation": "Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022. 10.1038/s41422-022-00618-w.", "ArticleIdList": ["PMC8771185", "35058606"]}, {"Citation": "Fischer WA, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14:eabl7430. doi: 10.1126/scitranslmed.abl7430.", "ArticleIdList": ["10.1126/scitranslmed.abl7430", "34941423"]}, {"Citation": "Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509\u201320. doi: 10.1056/NEJMoa2116044.", "ArticleIdList": ["10.1056/NEJMoa2116044", "PMC8693688", "34914868"]}, {"Citation": "Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold. Antivir Res. 2018;154:66\u201386. doi: 10.1016/j.antiviral.2018.04.004.", "ArticleIdList": ["10.1016/j.antiviral.2018.04.004", "PMC6396324", "29649496"]}, {"Citation": "Yates MK, Seley-Radtke KL. The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antivir Res. 2019;162:5\u201321. doi: 10.1016/j.antiviral.2018.11.016.", "ArticleIdList": ["10.1016/j.antiviral.2018.11.016", "PMC6349489", "30529089"]}, {"Citation": "Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 2020;79:710\u201327. doi: 10.1016/j.molcel.2020.07.027.", "ArticleIdList": ["10.1016/j.molcel.2020.07.027", "PMC7402271", "32853546"]}, {"Citation": "Agostini ML, Pruijssers AJ, Chappell JD, Gribble J, Lu X, Andres EL, et al. Small-molecule antiviral \u03b2-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93:e01348\u201319. doi: 10.1128/JVI.01348-19.", "ArticleIdList": ["10.1128/JVI.01348-19", "PMC6880162", "31578288"]}, {"Citation": "Xie Y, Yin W, Zhang Y, Shang W, Wang Z, Luan X, et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 2021;31:1212\u20134. doi: 10.1038/s41422-021-00570-1.", "ArticleIdList": ["10.1038/s41422-021-00570-1", "PMC8477624", "34584244"]}, {"Citation": "Li Y, Yang B, Quan Y, Li Z. Advancement of prodrug approaches for nucleotide antiviral agents. Curr Top Med Chem. 2021;21:2909\u201327. doi: 10.2174/1568026621666210728094019.", "ArticleIdList": ["10.2174/1568026621666210728094019", "34323189"]}, {"Citation": "Pharmaceuticals and Medical Devices Agency. Tokyo: Pharmaceuticals and Medical Devices Agency; c2022. Gilead Sciences. Section 2.7-Clinical Summary of Remdesivir Common Technical Document. 2020. p. 271. Available from: https://www.pmda.go.jp/drugs/2020/P20200518003/230867000_30200AMX00455_K100_1.pdf. Accessed 16 Feb 2022."}, {"Citation": "Spinello A, Maria VC, Anna LR, Roberto R, Cecilia B, Gabriele P, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158:104899.", "ArticleIdList": ["PMC7212963", "32407959"]}, {"Citation": "Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Catagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382:2327\u201336.", "ArticleIdList": ["PMC7169476", "32275812"]}, {"Citation": "Pharmaceuticals and Medical Devices Agency. Tokyo: Pharmaceuticals and Medical Devices Agency; c2022. Gilead Sciences. Section 2.6.4 Pharmacokinetics Written Summary of Remdesivir Common Technical Document. 2020. p. 127. Available from: https://www.pmda.go.jp/drugs/2020/P20200518003/230867000_30200AMX00455_I100_1.pdf. Accessed 16 Feb 2022."}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "2", "Day": "18"}, {"Year": "2022", "Month": "3", "Day": "3"}, {"Year": "2022", "Month": "3", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "12", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "17", "Hour": "5", "Minute": "32"}, {"Year": "2022", "Month": "3", "Day": "16"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35296780", "PMC8924727", "10.1038/s41401-022-00895-6", "10.1038/s41401-022-00895-6"]}}], "PubmedBookArticle": []}